NAA15 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:80155, Ga19, HGNC:30782, MIM:608000, MRD50, N-alpha-acetyltransferase 15, NatA auxiliary subunit, NAA15, NARG1, NAT1P, NATH, NM_057175, NP_476516, TBDN, TBDN100, XM_005263236, XP_005263293

Omim:OMIM:608000

Id:ENSG00000164134

Hgnc:HGNC:30782

Entrez:80155

Ensembl:ENSG00000164134

Description:N-alpha-acetyltransferase 15, NatA auxiliary subunit

N-alpha-acetylation is among the most common post-translational protein modifications in eukaryotic cells. This process involves the transfer of an acetyl group from acetyl-coenzyme A to the alpha-amino group on a nascent polypeptide and is essential for normal cell function. This gene encodes the auxillary subunit of the N-terminal acetyltransferase A (NatA) complex. [provided by RefSeq, Jan 2017]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NAA15's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NAA15.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NAA15.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NAA15.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NAA15.

Results found

Linked to

	Label	Description
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 3 V 0 TEMOZOLOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169152 3 V 6 IBRUTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 8 V 1 AZACITIDINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE225869 3 V 0 TEMOZOLOMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE169152 3 V 6 IBRUTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE176008 8 V 1 AZACITIDINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.